Worm.com

Guide to Spyware and AntiVirus Information

You are currently browsing the Worm.com weblog archives for the day Tuesday, May 20th, 2008.

 

Sponsors

Archive for May 20th, 2008

Crohn’s disease is a chronic autoimmune disease of unknown cause, characterized by inflammation of the gut wall triggered by an attack from the immune system. The immune system, which normally attacks invading viruses or bacteria, is somehow stimulated to attack the body’s own tissue (in this case, the gut wall).

A recent survey found there has been no change in the results from conventional treatment for Crohn’s (such as drugs) in the past 40 years.1 But there is hope. Recent medical research has identified several important factors that might trigger or feed the inflammation in Crohn’s disease. In my experience, when herbs and dietary change are used to control or neutralize these factors, the inflammation is more or less alleviated.

There seems to be a genetic cause to Crohn’s disease. The genetic defect linked to Crohn’s disease actually gives us an insight into its cause. The defect is in a gene that encodes the protein known as CARD 15.2 CARD 15 is involved in recognizing and activating the immune response to bacteria. So, a poor immune response to gut microbes could be a key piece in the jigsaw puzzle. This highlights a common misunderstanding about autoimmune disease. It’s not due to a strong immune system that is too powerful. In fact, autoimmune disease, as illustrated above, most likely results when there is some weakness in the immune system. Under-responsiveness in one part of the immune system might lead to an excessive response in another part.

Johne’s disease, which occurs in cattle, is very similar to Crohn’s disease. The main difference is that the cause of Johne’s disease is known: a close relative of the bacterium that causes tuberculosis. This is known as Mycobacterium avium subspecies paratuberculosis or MAP for short. In 1984, a group of Italian researchers began a major scientific controversy when they found MAP in the intestinal tissue of patients with Crohn’s disease.3 The implication was that, like Johne’s disease, Crohn’s disease also was caused by the presence of this micro-organism in the gut. Now, more than 20 years later, the evidence implicating MAP in Crohn’s disease is strong.4 One factor behind this proof is the use of sophisticated gene techniques to find MAP, which are similar to those used by crime labs to identify victims or criminals.

Where does the MAP in humans come from? It seems it originates from consuming the milk from cows infected with Johne’s disease. Pasteurization may not kill this organism, and this has led British food authorities to advise dairy farmers not to release the milk from infected cows into the human food supply.

The amount of MAP found in Crohn’s disease patients is not high, so whether the inflammation is directly caused by the bacterium or by the body’s excessive immune response to its presence is not clear. But what is clear is that some respected medical authorities are now suggesting that eliminating MAP might improve the disease.5

Other gut bacteria such as E. coli have been implicated in Crohn’s and may contribute to the chronic disease process.6 A leaky gut probably enables the breakdown products of such bacteria to enter the general circulation, further stirring up the immune system.7

Crohn’s Disease and Diet

It might seem obvious that diet could be an important factor in Crohn’s disease, since it is after all a chronic inflammation of the digestive tract. This is backed up by the well-known observation that Crohn’s patients placed on an elemental diet (food broken down into its basic components such as amino acids, sugars, vitamins, etc) improve substantially.8 Clinical studies using elimination diets found that symptomatic improvement resulted when patients were placed on diets free of gluten, dairy products and yeast.9

The yeast aspect is particularly fascinating. Several studies have found that Crohn’s disease patients have antibodies in their blood directed towards baker’s or brewer’s yeast (Saccharomyces cerevisiae).10 In fact, these antibodies are so characteristic their presence is now used as a diagnostic test for Crohn’s.11 While some scientists think this association is of no consequence, others feel removal of yeast from the diet could be beneficial.12

Herbs for Crohn’s Disease

One of the key herbs for Crohn’s disease is the Ayurvedic herb known as boswellia. The safety and efficacy of a boswellia extract was compared against mesalazine for the treatment of 102 patients with active Crohn’s disease in an eight-week randomized, double-blind study.13 Mesalazine is a synthetic drug used as the standard anti-inflammatory treatment in Crohn’s disease. The primary clinical outcome measured was the change in the Crohn’s Disease Activity Index. After therapy with Boswellia extract (3.6 g per day), the average index was reduced by 90, compared to a reduction of only 53 for the mesalazine group (4.5 g per day).

Other herbs useful for Crohn’s disease include garlic, golden seal and some essential oils (oregano and anise) to reduce pathogenic bacteria in the gut such as MAP. Either fresh, crushed garlic cloves or garlic powder product can be used. The latter mimics in the digestive tract what happens when you crush a fresh clove. In my practice, I use a bowel flora-rebuilding protocol which is based around these herbs.

Information provided by: Findarticles.com

Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google
  • Reddit
  • Slashdot
  • Spurl
  • Technorati
  • TwitThis

AVI BioPharma, Inc. (NASDAQ: AVII) today
announced that Patrick Iversen, Ph.D., AVI’s Senior Vice President of
Strategic Alliances, is presenting at the TIDES Oligonucleotide and Peptide
Technology and Product Development meeting in Las Vegas on Tuesday, May 20,
2008. The title of his presentation is “Manipulating the Immune Response
with Cell Penetrating Peptide Conjugated Phosphorodiamidate Morpholino
Oligomers” and is to feature the targeting of genes, such as interleukin-10
(IL-10), involved in the host immune response, with AVI’s proprietary
Phosphorodiamidate Morpholino Oligomers and arginine-rich peptides. IL-10
is considered a key regulator of immune response to infection from viruses,
bacteria and other organisms.

About AVI BioPharma

AVI BioPharma develops therapeutic products for the treatment of
life-threatening diseases using third-generation NeuGene® antisense drugs
and ESPRIT directed RNA alternative splicing technology. AVI’s ESPRIT
technology is initially being applied to potential treatments for Duchenne
muscular dystrophy. AVI’s NeuGene compounds are also designed to treat
cardiovascular restenosis in stent and coronary artery bypass graft (CABG)
procedures. In addition to targeting specific genes in the body, AVI’s
antiviral program uses NeuGene antisense compounds to combat disease by
targeting single-stranded RNA viruses, including Marburg Musoke and Ebola
Zaire viruses. More information about AVI is available at www.avibio.com .

“Safe Harbor” Statement under the Private Securities Litigation Reform Act
of 1995: The statements that are not historical facts contained in this
release are forward-looking statements that involve risks and
uncertainties, including, but not limited to, the results of research and
development efforts, the results of preclinical and clinical testing, the
effect of regulation by the FDA and other agencies, the impact of
competitive products, product development, commercialization and
technological difficulties, and other risks detailed in the company’s
Securities and Exchange Commission filings.

The information contained in this press release does not necessarily
reflect the position or the policy of the Government and no official
endorsement should be inferred.

AVI Press and Investor Contact:
Michael Hubbard
( Email Contact )
Director of Corporate Communications
(503) 227-0554

Information provided by: Findarticles.com

Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google
  • Reddit
  • Slashdot
  • Spurl
  • Technorati
  • TwitThis

SAN DIEGO — Quidel Corporation (NASDAQ:QDEL), a leading provider of rapid point-of-care (POC) diagnostic tests, and Prodesse, Inc., a biotechnology company focused on developing molecular diagnostic reagents for a variety of infectious diseases, announced today an agreement between the two companies to jointly promote Prodesse’s ProFlu+[TM] multiplex molecular diagnostic test within the United States. ProFlu+ is an FDA 510(k) cleared, real-time PCR, closed tube test that simultaneously detects Influenza A, Influenza B and respiratory syncytial virus (RSV), which together cause the vast majority of serious respiratory infections.

The agreement strengthens Prodesse’s own sales efforts with acute care representation by the Quidel sales and marketing teams. Caren Mason, president and CEO of Quidel, commented, "Our acute care customers look for leadership from Quidel in influenza management. By co-promoting this product, we are providing an alternative solution to those seeking a molecular complement to their rapid testing program." Tom Shannon, president and CEO of Prodesse, remarked, "Our partnership with Quidel will aid us in expanding our reach to the thousands of hospitals that utilize the many instruments that are capable of running ProFlu+."

Quidel will now have access to a new molecular product, particularly suited for the acute care laboratory market. The ProFlu+ test provides a complementary product offering to the Quidel QuickVue([R]) rapid influenza and RSV tests. As part of the agreement, Quidel earns a fee for all product placements.

According to the Centers for Disease Control (CDC), influenza is responsible for about 36,000 deaths and more than 200,000 hospitalizations in the U.S. each year1. The National Foundation of Infectious Diseases, in a report released in September 2007, indicates that influenza can be especially severe for those with high-risk conditions (e.g., diabetes and heart disease), and recent studies have also found that the illness may trigger up to 92,000 cardiac deaths per year nationwide2. The QuickVue Influenza A+B test is intended for use as an aid in the rapid differential diagnosis of acute influenza type A and B.

Respiratory syncytial virus is recognized by the American Academy of Pediatrics as the leading cause of pneumonia and bronchiolitis among children two years of age and younger. RSV is a common virus with symptoms that often resemble the common cold3. The QuickVue RSV test is intended for use as an aid in the diagnosis of acute RSV viral infections for symptomatic pediatric patients.

1 CDC, Page last updated November 16, 2007; Content Source: Coordinating Center for Infectious Diseases (CCID) National Center for Immunization and Respiratory Diseases (NCIRD).

2 National Foundation for Infectious Diseases, September 20, 2007.

3 Respiratory Syncytial Virus (RSV). American Academy of Pediatrics, et al., http://www.aap.org/pubed/ZZZSO05MASD.htm?&sub_cat=107 (accessed 1/16/2006).

About Quidel Corporation

Quidel Corporation serves to enhance the health and well being of people around the globe through the discovery, development, manufacturing and marketing of rapid diagnostic solutions at the point of care (POC) in infectious diseases and reproductive health. Marketed under the leading brand name of QuickVue([R]), Quidel’s portfolio of products currently includes tests that aid in the diagnosis of several disease or condition states, including influenza, respiratory syncytial virus, Fecal Occult Blood, Strep A, pregnancy, bacterial vaginosis, H. pylori and Chlamydia. Quidel’s products are sold to healthcare professionals with a focus on the physician office lab and acute care markets through leading medical distribution partners on a worldwide basis. Quidel’s Specialty Products Group (SPG) develops research products in the fields of oncology and bone health with potential future point-of-care applications. By building value in rapid diagnostic tests, Quidel provides leadership to the industry and among healthcare professionals allowing for the movement of patient testing out of the central laboratory setting and into the physician office, urgent care and other outpatient settings where rapid testing and treatment has an impact on clinical outcomes and provides an economic benefit. For more information, visit www.quidel.com, www.colorectal-test.com or www.flutest.com.

About Prodesse, Inc.

Prodesse is a biotechnology company focused on developing molecular diagnostic reagents for a variety of infectious disease applications. The company’s products are designed based on a combination of Prodesse’s patented technologies and other licensed technologies. Prodesse sells FDA 510(k) cleared products worldwide, CE Marked in vitro diagnostic kits outside the U.S. and research use only kits worldwide. The company’s products can be used on multiple nucleic acid extraction and real-time PCR platforms. Prodesse also operates a CLIA certified laboratory for testing services in the Midwest area. For more information about Prodesse and its products, call 888-589-6974 or go to www.prodesse.com.

Information provided by: Findarticles.com

Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google
  • Reddit
  • Slashdot
  • Spurl
  • Technorati
  • TwitThis

CHICAGO — CytoCore Inc. (OTCBB:CYOE), the developer of cost-effective, highly accurate screening systems for early detection of gynecological cancers and sexually transmitted diseases announced an exclusive agreement with QuantRx Biomedical Corporation (OTCBB:QTXB) to distribute its PadKit[R] Collection Kit to provide samples for Cytology and Human Papilloma Virus (HPV) diagnostics, for the worldwide women’s health laboratory market.

Richard Domanik, President and Chief Operating Officer of CytoCore stated, "We are excited to be able to expand our support of the worldwide women’s health market with this truly innovative product. QuantRx has done a remarkable job in perfecting the pad technology, and we are pleased to move into the next phase of product marketing through our partnership. QuantRx will be our exclusive manufacturer for this product, which allows us to introduce a new paradigm in cytology sample collection for gynecological cytology. PadKit([R]), which complements the capabilities of our SoftPap([R]) Collector, provides us with a convenient and largely technique independent means for collecting a gynecological sample for both conventional and AIPS-based cytological, HPV and other tests."

"CytoCore is focused on the Cytology market, and brings decades of expertise to this market. This agreement will allow QuantRx to accelerate its PAD technology to the market and focus our in-house R&D efforts on new applications," said William Fleming, QuantRx’s Chief Science Officer. "The completion of this project revalidates QuantRx’s strategic position in the diagnostic market as a developer and manufacturer of new products and cutting edge technology."

CytoCore, Inc.

CytoCore develops cost-effective, highly accurate screening systems for early detection of gynecological cancers and sexually transmitted diseases. Designed for easy deployment at a laboratory or at the point-of-care, the CytoCore suite of sample collection technologies assists in the detection of cervical, endometrial, and other cancers, as well as the Human Papilloma Virus. The CytoCore Solutions[TM] System is being developed to provide medical practitioners with highly accurate, low-cost, cervical and uterine cancer screening systems that can be seamlessly integrated into existing medical models. More information is available at: www.CytoCoreInc.com.

About QuantRx Biomedical (www.quantrx.com)

QuantRx Biomedical Corporation (OTCBB:QTXB) is a broad-based diagnostics company focused on the development and commercialization of innovative diagnostic products based on its patented technology platforms for the worldwide healthcare industry. With synergistic expertise in the discovery of diagnostic platforms and the commercialization of products for use by healthcare professionals and consumers, QuantRx is focused on providing more accurate, reliable, and faster diagnoses that result in improved patient care.

Certain statements in this release are forward-looking. These statements are based on CytoCore’s current expectations and involve many risks and uncertainties, such as the company’s inability to obtain sufficient financing, the possibility that clinical trials will not substantiate CytoCore’s expectations with respect to the CytoCore Solutions[TM] System, and other factors set forth in reports and documents filed by CytoCore with the Securities and Exchange Commission. Actual results may differ materially from CytoCore’s current expectation depending upon a number of factors affecting the Company’s business. These factors include, among others, risks and uncertainties detailed in the Company’s periodic public filings with the Securities and Exchange Commission, including but not limited to the Company’s Annual Report on Form 10-KSB for the year ended December 31, 2007. Except as expressly required by law, CytoCore undertakes no obligation to publicly update or revise any forward-looking statements contained herein.

COPYRIGHT 2008 Business Wire
COPYRIGHT 2008 Gale, Cengage Learning

Information provided by: Findarticles.com

Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google
  • Reddit
  • Slashdot
  • Spurl
  • Technorati
  • TwitThis

Lovaxin C Phase II Study and Protocol for Cervical Intraepithelial Neoplasia

A Randomized, Single Blind Placebo Controlled Phase 2 Study to Assess the Safety, Efficacy, and Immunogenicity of Vaccination with Listeria monocytogenes Expressing Human Papilloma Virus Type 16 E7 (Lovaxin C) for the Treatment Cervical Intraepithelial Carcinoma Stage 2/3

NORTH BRUNSWICK, N.J. — Advaxis Inc., (OTCBB: ADXS, http://www.advaxis.com.), a developmental biotechnology company, completed its filing of a new investigational new drug ("IND") application with the U.S. Food and Drug Administration ("FDA"). This filing follows the successful completion of a Phase I study overseas.

This application includes a Phase II protocol for Lovaxin C, Advaxis’ lead drug candidate, for the treatment of Cervical Intraepithelial Neoplasia ("CIN") to be conducted in the US. The filing requires a certificate of analysis for the Company’s second clinical batch, which is currently being made and is anticipated to be complete within the next few weeks. The CIN study is scheduled to begin this summer pending the completion of the IND and approval by the FDA.

CIN is a cervical condition caused by a sexually transmitted virus called the Human Papilloma Virus ("HPV") that can lead to invasive cervical cancer, if not diagnosed properly and left untreated. Currently, the standard treatment for late stage CIN is surgery to preclude invasive cancer, and there are approximately 250,000 cases of CIN treated this way in the US annually. Recent new vaccines can prevent occurrence of CIN if administered before HPV is contracted, but do not treat the disease itself.

"This trial is a potential major step forward in our clinical program," commented Advaxis Chairman and CEO Tom Moore. "Lovaxin C, our lead drug candidate, and our Listeria platform is quickly drawing the attention of such notable organizations within the medical community as the American Association for Cancer Research ("AACR"), the Cancer Research Institute ("CRI") and, most recently, the Gynecologic Oncology Group ("GOG"). We are encouraged by our Phase I results, and our ability to generate novel immunotherapies with considerable activity in animal models. Additional clinical trials with Lovaxin C and the introduction of new immunotherapies into clinical trials are planned."

About Advaxis, Inc.

Based in North Brunswick, New Jersey, Advaxis is developing proprietary Listeria monocytogenes ("Lm") cancer vaccines based on technology developed by Dr. Yvonne Paterson, Professor of Microbiology at the University of Pennsylvania and Chairperson of Advaxis’ Scientific Advisory Board. Advaxis is developing therapeutic cancer vaccines that enhance the immune system’s cancer fighting abilities through its proprietary Lm based system, which utilizes multiple simultaneous immunological mechanisms to fight cancer safely.

Advaxis’ lead Listeria vaccine candidate, Lovaxin C, targets HPV-associated cancers such as cervical and head and neck. Current Lm vaccines in development target prostate, breast, ovarian and other cancers. Recently, Advaxis completed a Phase I/II clinical trial of Lovaxin C. A Phase II clinical trial is planned for patients with cervical intraepithelial neoplasia ("CIN"). The company intends to start this study in CIN I/II patients in the summer of 2008. The Lm platform also has applications in the fields of infectious disease and autoimmune disorders.

For further information on the Company, please visit: http://www.advaxis.com.

About Lovaxin C Vaccine

Advaxis’ Listeria technology platform uses modified Listeria monocytogenes to deliver a tumor-specific antigen fusion protein. Bioengineered Listeria that are attenuated and secrete Advaxis’ proprietary fusion protein, have the ability to generate a robust immune response, break immune tolerance to cancer and produce an unusually strong and effective multi-level therapeutic immune response to existing cancer and other diseases.

Advaxis’ Listeria-based technology is based on over a decade’s worth of work by Dr. Yvonne Paterson in her laboratory at the University of Pennsylvania. The Company’s proprietary antigen fusion protein technology, stimulates innate immunity, both arms of the adaptive cellular immune system, suppresses regulatory T cells that inhibit many vaccines in the function of activated tumor-killing cells and has other anti-tumor effects.

Unlike prophylactic vaccines, Lovaxin C was designed to treat women who have already developed cervical cancer as a result of contracting a human papilloma virus ("HPV") infection, which is the most prevalent sexually transmitted disease in the US. Current products on the market are ineffective in treating HPV-infected women.

For further information on Lovaxin C, please visit: http://www.advaxis.com/lc.htm

Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company’s current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company’s actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company

Information provided by: Findarticles.com

Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google
  • Reddit
  • Slashdot
  • Spurl
  • Technorati
  • TwitThis

If you question any system administrator as to
“indispensable” software applications or utilities, you’re likely to get
any number of answers. You’re likely to also find some commonalities,
though, such as anti-virus, firewall, backup and defragmentation. But in
the case of defrag , the
defragmentation technology being used is a key factor — one that bears
examination by any enterprise.

File fragmentation occurs on all computers. Invented to better utilize disk
space, fragmentation breaks files into pieces (fragments). While the disk
space is indeed better utilized, a serious problem is entered in due to the
multiple extra I/Os required to access all the fragments of a file.
Performance is drastically affected, hard drive life is shortened by a
third to half, and system reliability can also come into question.

For many years, the common defragmentation solution has been scheduled
defragmentation; at times when a system isn’t in use, defragmentation could
be scheduled to run. In today’s computing environment, however, with its
enormous files and huge disk drive capacities, scheduled defrag is no longer able to keep up
with the fragmentation rates.

Many companies have found that the fully automatic defragmentation provided
by Diskeeper® is the only real way to keep pace with fragmentation.
Utilizing a proprietary technology called InvisiTasking(TM), Diskeeper
works invisibly, in the background, utilizing resources that would
otherwise be idle. There is no negative performance hit by the defrag process, and performance is
always maximized.

“The value of this product to our company is indispensable,” says John Kimm
of The Power Station, an online radio station and music store. “Diskeeper
prevents downtime of our servers and websites so we do not lose customers.”

“Diskeeper is just one of those ‘must have’ utilities in my eyes,” agrees
Shelly Shinnick, Systems Administrator for Pate Engineers, Inc. of Houston,
Texas. “We have a large file server, full of AutoCAD drawings that get
heavily fragmented since they are constantly being modified. The server has
4TB of attached storage and is at 80-90% capacity. I was getting daily
complaints about the file server being slow — multiple times a day. I
installed Diskeeper and immediately the complaints stopped.”

“After I installed Diskeeper, there wasn’t really anything to do; it just
sits there and runs in the background doing what it does,” Shinnick
concludes.

In today’s computing environments with their constant access and frantic
rates of fragmentation, Diskeeper’s fully automatic solution really is
indispensable to constant uptime and performance.

Contact:
Colleen Toumayan
Email: ctoumayan@diskeeper.com

Information provided by: Findarticles.com

Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google
  • Reddit
  • Slashdot
  • Spurl
  • Technorati
  • TwitThis

CALGARY, May 20 /PRNewswire-FirstCall/ — Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) ("Oncolytics") today announced that it has been granted U.S. Patent 7,374,752 entitled "Reovirus for the Treatment of Cellular Proliferative Disorders." The claims cover pharmaceutical compositions which comprise various recombinant reoviruses.

"This patent provides the Company with additional patent protection for reovirus compositions in the United States," said Mary Ann Dillahunty, Vice President of Intellectual Property for Oncolytics.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics’ clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com/

This news release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including among others, the Company’s belief as to the importance of the issuance of this patent, the safety and efficacy of the reovirus, the Company’s expectations as to the potential applications of the patented technology and other statements relating to anticipated developments in the Company’s business and technologies, involve known and unknown risks and uncertainties that could cause the Company’s actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the efficacy of REOLYSIN(R) as a cancer treatment, the success and timely completion of clinical studies and trials, uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company’s quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements.

CONTACT: Oncolytics Biotech Inc., Cathy Ward, 210, 1167 Kensington Cr NW, Calgary, Alberta, T2N 1X7, Tel: (403) 670-7377, Fax: (403) 283-0858, cathy.ward@oncolytics.ca; The Equicom Group, Nick Hurst, 325, 300 5th Ave SW, Calgary, Alberta, T2P 3C4, Tel: (403) 538-4845, Fax: (403) 237-6916, nhurst@equicomgroup.com; The Investor Relations Group, Erika Moran, 11 Stone St, 3rd Floor, New York, NY 10004, Tel: (212) 825-3210, Fax: (212) 825-3229, emoran@investorrelationsgroup.com

COPYRIGHT 2008 PR Newswire Association LLC
COPYRIGHT 2008 Gale, Cengage Learning

Information provided by: Findarticles.com

Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google
  • Reddit
  • Slashdot
  • Spurl
  • Technorati
  • TwitThis

Dear Heloise: Three hours from home, my 64-year-old husband ended up in an emergency room with horrible pains, cold chills and nausea. He called me on his cell phone and told me the name of the town, but was too ill to even go to the desk and find out the name of the hospital. Getting phone numbers from information, I finally found out where he was, only to be shut out of getting any information because of the patient-privacy law — HIPAA. Was he having a heart attack? Was he dying? They would not tell me. Fortunately, it turned out to be only a violent stomach virus.

As a result of this frightening episode, we now have copies of our health directives, HIPAA access forms and medical information in clearly marked envelopes. Every person, including teens, should have a written, signed, witnessed directive as to what he or she wants done in case of emergencies, including who can be informed. No next of kin should be denied access to a loved one’s health status because of paperwork! A copy should also be in your files at your primary-care doctor’s office. –Jan L., Bella Vista, Ark.

Jan, thank you for sharing your scary experience so others don’t have to go through this. –Heloise

Dear Heloise: I find it difficult to hold on to the large-size bottles of hair spray while applying it to my hairdo because they are so heavy. I don’t even have arthritis. But I found out that using a travel-size hair-spray bottle works best for everyday use. When empty, just refill it from the large bottle. Hope this helps others like it has helped me. –Sharon McMillan, Danville, Ky.

Dear Heloise: The lint removers with tear-off sticky rollers are perfect for cleaning the cloth speaker covers that gather dust so badly. –Pam Holt, Newton, N.C.

Dear Heloise: At my mother’s funeral, I took two pictures of each arrangement received — (1) the whole arrangement and (2) a close- up of the card. Not only did this help identify each for me when it came time to send thank-you notes, but for those who were unable to visit in person, I enclosed a copy of the picture for the sender. Bonus for me — pictures to have and hold always.–Kathy W., via e- mail

Kathy, this hint will be very helpful and could also be carried over to a shower — instead of finding someone to write a gift list as gifts are opened, take pictures with a digital camera and erase when done or keep for insurance purposes!–Heloise

Dear Heloise: After using a gift card, write the balance with a permanent marker on the card. You will always know how much is left without carrying around receipts. –Donna, via e-mail

Dear Heloise: My wife reads your column in the Houston Chronicle every time it appears, and I consider the hints wonderful.

She did something for me today that was out of her own sweetness and for my comfort. I have a home-based office with a comfortable chair, except when I take off my shirt and tie (I am a country boy and do that to relax at home). The chair is inexpensive plastic, so I stick to it. I put a towel on the back, but my wife found one of my T-shirts that I rarely wear, turned the sleeves inside out and slipped it over the back of the chair. It is perfect, and if I decided to wear it, it could be washed. After almost 41 years, she is a keeper. –Henry A. Stanaland, Houston

Dear Heloise: For an impromptu bottle/anything cleaner, grab your kitchen whisk, enrobe it with a dishcloth and put a rubber band around the base to hold the cloth in place. Voila!–Dennis T., San Diego

Send a money-saving or timesaving hint to Heloise, P.O. Box 795000, San Antonio, TX 78279-5000, or you can fax it to 210-435- 6473 or e-mail it to Heloise@Heloise.com. I can’t answer your letter personally but will use the best hints received in my column.

[copyright] King Features Syndicate Inc.

Copyright C 2008 Deseret News Publishing Co.
Provided by ProQuest Information and Learning Company. All rights Reserved.

Information provided by: Findarticles.com

Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google
  • Reddit
  • Slashdot
  • Spurl
  • Technorati
  • TwitThis

An investigational smallpox drug may also protect against adenovirus, which causes upper respiratory infections and is one of the many viruses that causes the common cold.

Currently, there are no drugs specifically approved to treat adenovirus. In part, this is because there have been no animal models in which to test new drugs, something that needs to be done before new drugs can be tested in humans.

Saint Louis University researchers and colleagues report two important advances. They identified an animal model (Syrian golden hamsters) suitable for adenovirus testing and a drug that successfully attacks adenovirus in the hamsters.

hexadecyloxypropyl-cidofovir (CMX001) — is currently being developed to protect against smallpox or monkeypox, and as an antiviral agent in transplant patients.

The Saint Louis University team found that CMX001 protected the hamsters against adenovirus when the drug was given both before infection with the virus and after infection. The drug worked …


Read the full article with a Free Trial at MyWire.

Information provided by: Findarticles.com

Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google
  • Reddit
  • Slashdot
  • Spurl
  • Technorati
  • TwitThis

PROVO — Despite their best efforts to get out of it, Luella and Lacy Leghorn are among the 450 sentinel chickens posted throughout the state to herald West Nile virus activity.

Sentinel chickens — slick cream-colored leghorn girls — were stacked seven cage layers deep in steel mesh towers Monday for the annual distribution, which drew mosquito abatement staffers statewide to the Utah County mosquito abatement office.

The placid poultry are a reservoir for the virus and one of the first places the virus is typically detected, according to Utah County Health spokesman Lance Madigan. Unlike horses and people, which may become very sick when infected but are “dead-end” hosts, the sentinel chickens show no symptoms. So blood is drawn from their wings each week to check for it.

Ideal conditions for the virus-laden mosquito population include a wet spring and very hot summer, but it’s impossible to predict how severely West Nile will hit an area, said Gary Hatch, Davis mosquito abatement director. Around April, mosquito control teams go after larvae, then spread their efforts to include adult winged beasties, an effort that continues well into September. In Utah, urban dwellers C. pipiens and marsh-loving C. tarsalis carry the virus.

People can take steps to protect themselves. Health officials promote wearing long sleeves and pants when outdoors from dusk to dawn, the hours these particular mosquitoes snack. They urge use of mosquito repellent, especially with DEET. And they counsel cutting back grass and getting rid of pooled water in the yard, among other steps.

The mosquito abatement crews brought everything from dog crates to slatted wooden boxes to transport the chickens, which will be placed in small groups at preselected sites known for mosquito activity.

Needs vary in communities. Salt Lake City’s mosquito abatement assistant manager Dennis Kiyoguchi, for instance, picked up 20 birds, as did Magna and South Salt Lake to round out coverage in Salt Lake County. Utah County maintains four flocks of five birds each, while Brett Marchant and Whitney Peck grabbed 30 birds for Summit County. Hatch picked up 60 birds that will be distributed in a dozen Davis County locations.

Early in the process, Luella Leghorn evaded capture and claimed a shady spot on the trailer under the stacked cages, until Randy Sessions, Box Elder’s mosquito abatement manager, grabbed her for the trip north, along with 60 others that will be split between his district, Bear River and Logan. Magna’s Ryan Lusty cornered Lacy as she was sneaking across the parking lot.

John Johnson picked up 10 sentinels for two little flocks in Sevier County, then loaded an extra 20 that will serve as “reservists” for southern Utah. Sevier, he noted, is one of the rare Utah counties that has had no detected West Nile virus, although one resident got the virus while out of the area. “It’s not if, but when,” Johnson said.

Mosquito pools are also tested statewide for West Nile. But this year, the state lab will not test dead corvids — a bird family including crows, jays and magpies — and raptors for the virus, although Salt Lake Valley Health Department will as part of a study. “It wasn’t the most effective surveillance tool we’ve ha